Comparative Pharmacology
Head-to-head clinical analysis: BIORPHEN versus CENOBAMATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIORPHEN versus CENOBAMATE.
BIORPHEN vs CENOBAMATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Biorphen (phenylephrine) is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction and increased blood pressure.
Cenobamate is a tetrazole-derived anticonvulsant that modulates GABA A receptors, preferentially inhibiting the persistent sodium current and activating potassium currents (M-current). It also enhances GABA-mediated inhibition and reduces excitatory neurotransmitter release.
Adults: 2.5-10 mg IV/IM/SC every 2-4 hours as needed for pain; oral: 10-20 mg every 4 hours as needed.
Cenobamate 200 mg orally once daily initially, titrated weekly by 50 mg to a target dose of 400 mg once daily; maximum 400 mg/day.
None Documented
None Documented
Terminal elimination half-life: 2–4 hours (short-acting opioid; context: requires q4h dosing for sustained analgesia).
The terminal elimination half-life is approximately 10-17 hours in adults. Steady-state is achieved within 2-3 days. In patients with moderate to severe hepatic impairment, half-life may be prolonged.
Renal: 90% as glucuronide conjugates; Fecal: 10% (unabsorbed/biliary).
Renal excretion accounts for approximately 92% of the administered dose, with 62% as unchanged drug and 30% as metabolites. Fecal excretion is minimal (<2%).
Category C
Category C
Anticonvulsant
Anticonvulsant